The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis This phase 2 study aimed to determine the efficacy and safety of the combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) and its effect on bone remodeling and angiogenesis in relapsed/refractory myeloma. Bortezomib (1.0 mg/m 2 ) was given on days 1, 4, 8, 11, oral melphalan (0.15 mg/kg) on days 1-4, whereas thalidomide (100 mg per day) and dexamethasone (12 mg/m 2 ) were administered on days 1-4 and 17-20 of a 28-day cycle, for four cycles. Patients without disease progression continued for up to eight cycles. VMDT effect on bone remodeling was evaluated by measuring osteoclast regulators (soluble receptor activator of nuclear factor-j B ligand/osteoprotegerin ratio, osteopontin, macrophage inflammatory protein-1a), dickkopf-1 protein, bone resorption and formation markers, whereas its effect on angiogenesis was assessed by measuring serum vascular endothelial growth factor, angiogenin, angiopoietin-2 and basic fibroblast growth factor, after four cycles and at the study end. A total of 62 patients were enrolled. The overall response rate was 66%: CR 13%, vgPR 27% and PR 26%. Median time to response was 35 days and median time to progression was 9.3 months. Common adverse events included cytopenias, peripheral neuropathy and infections. No patient experienced deep-vein thrombosis. VMDT reduced angiogenic cytokines, osteoclast regulators, dickkopf-1 and bone resorption. We conclude that VMDT with intermittent thalidomide is an active and well-tolerated regimen for relapsed/refractory myeloma, affecting abnormal bone remodeling and angiogenesis.
Introduction
Interactions between multiple myeloma (MM) cells and the marrow microenvironment are crucial for myeloma growth and resistance to antimyeloma therapy.
1 Bortezomib (V) and thalidomide (T) have proven antimyeloma effect and exert their action partly through perturbation of the MM microenvironment. 2, 3 Furthermore, bortezomib enhances the cytotoxic potential of other agents, such as melphalan (M) and dexamethasone (D) in resistant cell lines. 4, 5 Both bortezomib and thalidomide also showed an in vivo synergistic effect when combined with melphalan. [6] [7] [8] In our experience, MDT with intermittent thalidomide was active in elderly, untreated, MM patients, 9 whereas intermittent thalidomide combined with cyclophosphamide and dexamethasone pulses was also effective in previously treated patients. 10 On the basis of these data, we hypothesized that combining V and intermittent T, to target both myeloma cells and microenvironment, with MD may help overcome resistance and enhance the efficacy of these agents in relapsed/refractory MM.
Bortezomib and thalidomide, either as monotherapy or in combination with dexamethasone, may also affect bone metabolism and angiogenesis in MM. [11] [12] [13] [14] [15] However, this effect has not been defined when they are combined with other antimyeloma agents. The aim of this phase 2 study was to determine the efficacy and safety of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) regimen with intermittent thalidomide and evaluate its effect on angiogenesis and bone remodeling in relapsed/refractory myeloma.
Patients and methods

Patients
Patients with refractory or relapsed myeloma after at least one prior treatment were eligible. Other inclusion criteria included age X18 years, Karnofsky performance status X60%, platelet count X50 Â 10 9 /l, neutrophil count X1.5 Â 10 9 /l, serum ALT/AST p3-fold of upper normal limit (UNL), serum bilirubin p2-fold of UNL and expected survival X3 months. Patients with peripheral neuropathy (PN) Xgrade 2 were not included.
The study was approved by the local ethical committees in accordance with the Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. All patients provided informed consent before entering into the study.
Treatment schedule
The primary objectives of the study were to determine response rate and evaluate safety and toxicity of VMDT. The secondary objectives were to assess the time to progression (TTP), time to next treatment (TtNT), overall survival (OS) and the effect of VMDT on bone metabolism and angiogenic cytokines.
Bortezomib was administered at a dose of 1.0 mg/m 2 , i.v., bolus, on days 1, 4, 8 and 11 of a 28-day cycle, whereas melphalan was given orally at a dose of 0.15 mg/kg per day on days 1-4. Thalidomide was administered intermittently at a dose of 100 mg per day on days 1-4 and 17-20, and dexamethasone was given at a dose of 12 mg/m 2 on days 1-4 and 17-20. The regimen was repeated on day 28 if the neutrophil count was 41.5 Â 10 9 /l and the platelet count was 450 Â 10 9 /l. Patients without progressive disease (PD) after cycle 4 continued for up to eight cycles. Bortezomib dose was reduced to 0.7 mg/m 2 on days 1, 4, 8, 11 and subsequently to 0.7 mg/m 2 on days 1 and 8 in patients who experienced grade 2 PN whereas treatment was withheld for patients with grade X3 nonhematological toxicity or grade 4 hematological toxicity until improvement to grade 1 or better. All patients received prophylaxis with valacyclovir 500 mg daily and TMP/SMX one double-strength tablet thrice weekly. Prophylactic anticoagulation was not given. All patients were receiving zoledronic acid (4 mg, i.v., monthly) before and during study period.
Pretreatment, efficacy and safety assessments
Pretreatment evaluations consisted of patients' history, physical examination, standard hematology and biochemistry, electrocardiogram and chest radiographs. Neurological examinations were conducted by study physicians at screening, the beginning of each cycle and study conclusion. A negative pregnancy test was required for all women of childbearing potential. Skeletal X-rays were performed at screening, at the end of the study and whenever needed according to patients' symptoms.
Evaluation of response was monitored every 4 weeks using the uniform response criteria of the International Myeloma Working Group but without evaluation of stringent complete response (CR). 16 On an intention-to-treat basis, patients who discontinued treatment before a response could be assessed were rated as having PD. All patients who received at least 1 day of VMDT were eligible for assessment of toxicity. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria version 2.0.
Evaluation of bone remodeling and angiogenesis
Bone remodeling was evaluated by the measurement of several serum biochemical indicesF(1) osteoclast regulators: soluble receptor activator of nuclear factor-k B ligand (sRANKL), osteoprotegerin (OPG), osteopontin (OPN) and macrophage inflammatory protein-1a (MIP-1a); (2) dickkopf-1 (Dkk-1): inhibitor of osteoblast differentiation; (3) bone resorption markers: C-telopeptide of collagen type-I (CTX), and tartrateresistant acid phosphatase isoform-5b (TRACP-5b) and (4) bone formation markers: bone-specific alkaline phosphatase (bALP), osteocalcin (OC) and C-propeptide of collagen type-I (CICP), using enzyme-linked immunosorbent assay (ELISA) methodology as previously described. 11, 17, 18 Serum levels of vascular endothelial growth factor (VEGF), angiogenin (Ang), angiopoietin-2 (Ang-2) and basic fibroblast growth factor (bFGF) were also determined using ELISA as previously described. 19 Collection of serum samples for the evaluation of the above molecules was performed at screening, on day 28 of cycle 4 and at the study end. Then serum samples were stored at À70 1C until the day of measurement. Samples from the same patient were measured on the same ELISA plate. The results were compared with those of patients with relapsed/refractory myeloma who received the combination of bortezomib± dexamethasone (V ± D) or intermediate doses of thalidomide plus dexamethasone (TD). The characteristics as well as the results of bone remodeling markers of these patients had been previously described. 11, 12 The molecules that had not been evaluated previously were measured for the purpose of this analysis using available serum. Dkk-1 was not measured in TD patients due to lack of available serum. Furthermore, a total of 42 healthy control donors (24 male/18 female; median age 68 years, range: 43-79 years) were also tested. For these subjects, there was no evidence of bone disease (osteoporosis/osteoarthritis), no use of medication that could alter the normal bone turnover during the past 6 months, and no evidence of cardiovascular or neurological disease, inflammation, increased platelet count or any other disorder that could alter angiogenesis.
Statistical analysis
Data were analyzed as of July 2007. Mann-Whitney U-test was used to evaluate differences between patients and controls or patients who received V ± D or TD. Wilcoxon rank test was used to estimate differences between patients at different time points and differences between responders and nonresponders along with Student's t-test. Spearman's nonparametric correlation test was used to determine the correlations between evaluated parameters. The Kaplan-Meier method was used to estimate OS, TTP and TtNT probabilities, with differences compared by the two-sided log-rank test to identify potential prognostic factors. We performed univariate analyses using Fisher's exact test for categorical factors and logistic regression for continuous factors. Variables found to be statistically significant at the Po0.2 level were entered into a Cox proportional hazards regression analysis that employed a backward stepping procedure to identify the more important factors with independent significance. Time to response, TTP and OS were calculated as described previously. 16 TtNT was calculated from the time of enrollment until the date of next therapy administered. All P-values were two sided and confidence intervals (CIs) refer to 95% boundaries. Prior bortezomib, n (%)
Results
Patients and response data
6 (10) Abbreviations: ASCT, autologous stem cell transplantation; HDM, highdose melphalan.
VMDT regimen in refractory/relapsed myeloma E Terpos et al shown in Table 1 . The median number of VMDT cycles received was 6 (range: 1-8), whereas the median time on treatment (from treatment initiation to last Velcade dose) for all patients was 4.8 months (range: 0.1-7.8 months). More specifically, 5 patients (8.1%) received only one cycle of therapy, 3 (4.8%) received two cycles, 5 (8.1%) three cycles, 11 (17.7%) four cycles, 6 (9.7%) five cycles, 3 (4.8%) six cycles, 2 (3.2%) seven cycles, whereas 27 patients (43.5%) received eight cycles of VMDT. The overall response rate was 66% (41 of 62 patients): 8 patients (13%) achieved an immunofixation negative CR, 17 patients (27%) a very good partial remission (vgPR) and 16 patients (26%) a PR. The median time to response was 35 days (range: 10-150 days). Total 17 patients (27%) had responded after the first cycle, 32 (52%) after the second cycle and 39 (63%) had responded after the fourth cycle. Three patients (5%) died within the first two cycles: two due to septicemia and one due to necrotizing fasciitis. According to treatment protocol, 38 patients continued for more than four cycles and 27 patients completed eight cycles of VMDT. With further treatment, two patients who had stable disease after four cycles achieved PR, whereas eleven patients, who had PR, improved their responses further (five achieved CR and six vgPR). Table 2 depicts response according to disease status and prior treatments; patients with prior resistance to thalidomide had a lower likelihood of response (40 vs 75%, P ¼ 0.017). High-dose therapy (HDT) and thalidomide had been previously administered to 13 patients, whereas 13 patients had received thalidomide and melphalan; the overall response rate was 61.5 (8 of 13) and 69.2% (9 of 13) for these two subcategory patients, respectively. Furthermore, only three patients had received previously thalidomide, melphalan and bortezomib; of these patients one responded to VMDT. Four patients had also extramedullary plasmacytomas: three in the skin and one in the liver; extramedullary disease did not respond to VMDT.
Toxicity
All adverse events reported in this study are shown in Table 3 . Grade 4 events, excluding lymphopenia, occurred in 15% of the patients and included thrombocytopenia (5%), neutropenia (5%), and three fatal infections. PN was observed in 39 patients:
19 patients (30.6%) developed grade 1 PN, 14 (22.6%) grade 2 PN and 6 (9.7%) grade 3 PN. At study entry 12 patients had grade 1 PN due to prior use of thalidomide; of these, 7 developed grade 2 and 5 grade 3 neuropathy. No patient developed grade 4 neuropathy and no patient developed deep-vein thrombosis (DVT).
A total of 27 patients (43.5%) experienced at least one infectious episode, most were viral or bacterial infections of the upper respiratory tract. Six patients developed grade 3 infections and three grade 4 infections. Five patients developed herpes zoster (all had discontinued valacyclovir while on VMDT due to gastrointestinal problems; in total seven patients discontinued valacyclovir while on study), one patient experienced hepatitis B flare and one fatal Pneumocystis carinii pneumonia. Overall, 16 patients (25.8%) required a reduction of bortezomib dose at least once, and 14 (22.5%) discontinued treatment because of adverse events.
Effect on bone metabolism and angiogenic cytokines
At study entry, the skeletal survey revealed that 10 patients (16.1%) had no lytic lesions (group A), whereas 14 patients (22.5%) had 1-3 lytic lesions (group B) and 38 patients (61.2%) had 43 lytic lesions and/or a pathological fracture. At baseline, patients had increased serum levels of all osteoclast regulators and bone resorption markers compared with controls (Table 4) . In contrast, bone formation markers were markedly reduced, whereas serum Dkk-1 was increased. Patients of group C had increased levels of sRANKL (median: 0.78 pmol/l), sRANKL/ OPG ratio (0.09), MIP-1a (97.9 pg/ml), OPN (88.2 ng/ml), Dkk-1 (162.4 ng/ml), CTX (0.92 ng/ml) and TRACP-5b (3.12 U/l) compared with patients of groups A þ B (median values 0.21 pmol/l, 0, 28.4 pg/ml, 31.0 ng/ml, 55.8 ng/ml, 0.39 ng/ml and 2.02 U/l, respectively; Po0.01 for all comparisons). Furthermore, group C patients had reduced bALP (12.8 U/l vs 23.4 U/l, Po0.001) and CICP levels (55.0 ng/ml vs 16.8 ng/ml, Po0.01) but not of OC compared with all others. There were no differences between groups C and A þ B in terms of angiogenic cytokines.
The administration of VMDT resulted in a significant reduction of sRANKL (Figure 1a) , sRANKL/OPG ratio, MIP-1a 
VMDT regimen in refractory/relapsed myeloma E Terpos et al Table 4 Median values of markers of bone metabolism and angiogenic cytokines at baseline, after four cycles of VMDT and at the end of the study Abbreviations: bALP, bone-specific alkaline phosphatase; bFGF, basic fibroblast growth factor; CICP, C-propeptide of collagen type-I; CTX, C-telopeptide of collagen type-I; Dkk-1, dickkopf-1; MIP-1a, macrophage inflammatory protein-1a; MM, multiple myeloma; ND, nondetectable; OC, osteocalcin; OPN, osteopontin; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-k B ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform-5b; VEGF, vascular endothelial growth factor. a n ¼ 22 (13 M/9 F, median age 66 years) for Dkk-1 measurement.
Parameter
VMDT regimen in refractory/relapsed myeloma (Figure 1d ), TRACP-5b and Dkk-1 after four cycles, along with a significant increase of CICP, a marginal increase of OC and no alterations in bALP levels. Similar results were obtained at the end of the study (Table 4) . During study period only one patient, who experienced PD, developed a pathological fracture. In terms of angiogenic cytokines, all studied molecules were increased at baseline and were reduced at the end (Table 4) . Percentage changes of TRACP-5b strongly correlated with those of CTX (r ¼ 0.60, Po0.0001) and OC (r ¼ À0.604, Po0.0001), although there was strong correlation between percentage increases of OC and CICP (r ¼ 0.638; Po0.0001). Patients who received VMDT showed a greater reduction of MIP-1a, OPN, VEGF and bFGF compared with those who received V ± D or TD, in whom VEGF and bFGF were increased (Table 5 ). The reduction of bone resorption was similar with that achieved with V ± D or TD, whereas VMDT produced a more rapid reduction of sRANKL and sRANKL/OPG ratio compared with TD. In terms of bone formation, V ± D patients showed a greater increase of both bALP ( Figure 2 ) and OC but not of CICP compared with VMDT patients, mainly due to a greater reduction of Dkk-1. Furthermore, VMDT patients showed a significant increase of OC and CICP compared with TD patients who had a reduction of these molecules.
Time to progression and survival
Median TTP was 9.3 months (95% CI: 8.3-10.3; Figure 3a) . Factors that correlated with inferior TTP in univariate analysis were thalidomide resistance (P ¼ 0.01), increased Ang (P ¼ 0.066) and sRANKL/OPG ratio (P ¼ 0.081). In the multivariate analysis sRANKL/OPG ratio (P ¼ 0.015) and serum Ang (P ¼ 0.018) remained significant.
A total of 42 patients received further treatment and median TtNT was 8.8 months (95% CI: 7.2-10.4; Figure 3b ). In univariate analysis Dkk-1 (P ¼ 0.007) and OPG (P ¼ 0.046) were significant predictors of TtNT but in multivariate analysis only Dkk-1 (P ¼ 0.007) had independent prognostic value. VMDT regimen in refractory/relapsed myeloma E Terpos et al Abbreviations: Ang, angiogenin; bALP, bone-specific alkaline phosphatase; bFGF, basic fibroblast growth factor; CICP, C-propeptide of collagen type-I; CTX, C-telopeptide of collagen type-I; Dkk-1, dickkopf-1; MIP-1a, macrophage inflammatory protein-1a; ND, nondetectable; NP, not performed; NS, not significant; OC, osteocalcin; OPN, osteopontin; OPG, osteoprotegerin; sRANKL, soluble receptor activator of nuclear factor-k B ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform-5b; VEGF, vascular endothelial growth factor; VMDT, bortezomib, melphalan, dexamethasone and intermittent thalidomide.
VMDT regimen in refractory/relapsed myeloma
E Terpos et al
The median OS has not been reached yet, but lower bound of 95% CI is 19.5 months (Figure 3c ). Multiple factors correlated with inferior OS in univariate analysis: no response to VMDT (Po0.001), VMDT courses o4 (P ¼ 0.003), increased levels of sRANKL/OPG either as a continuous variable or as a dichotomous at median (P ¼ 0.003; Figure 4 ), Dkk-1 (P ¼ 0.021), VEGF (P ¼ 0.034), Ang (P ¼ 0.036) and presence of lytic disease (P ¼ 0.047), whereas there was a trend for thalidomide resistance (P ¼ 0.063), previous melphalan therapy (P ¼ 0.06) and CTX (P ¼ 0.06). There were no differences in outcome among patients who received VMDT at first relapse or later in the course of their disease. In multivariate analysis only baseline levels of Dkk-1 (P ¼ 0.013) and sRANKL/OPG ratio (P ¼ 0.001) had independent prognostic value for OS.
Discussion
After the administration of VMTD we observed an overall response rate of 66% with 40% of the patients achieving CR or vgPR. This CR þ vgPR rate in our study appeared higher than that observed with combinations of bortezomib plus melphalan (12%) 7 or VTD (16%) 20 and comparable to that reported with the combination of VMPT (43%). 21 It is important to notice that even patients who had received previously thalidomide and HDT or thalidomide and melphalan achieved overall response rates of between 60 and 70%. Improvement of CR/vgPR may be an important study end point because these are considered significant variables associated with longer survival. 22, 23 The median time to response after VMDT was only 5 weeks, that is among the fastest reported in trials of relapsed/refractory MM. The biweekly schedule of bortezomib administration, which is the standard dosing schedule for bortezomib in the majority of combination studies due to pharmacokinetic reasons, and the relatively high dose of dexamethasone used in this study may have contributed to the fast response associated with VMDT. Furthermore, we used this dexamethasone dosage based on our previous encouraging experience with MDT and CDT. 9, 10 A quick control of myeloma may be important in such patients, many of whom have a rapidly progressing disease. In our study, almost all PRs occurred before the administration of the fifth cycle. However, with further treatment the percentage of patients who achieved CR þ vgPR increased further.
Most adverse events in our study were manageable although a 22% of discontinuation rate for toxicities was not insignificant. Hematological toxicity was the most common adverse event, although three early deaths occurred due to infections in patients with severe neutropenia. Valacyclovir prophylaxis was very effective in preventing herpes-zoster reactivation. However discontinuation of prophylaxis while on treatment resulted in five episodes of reactivation; thus prophylaxis is necessary at least during treatment period. With intermittent administration of thalidomide there were no episodes of DVT in our study despite the absence of prophylactic anticoagulation. 24 Furthermore, grade 3 PN was recorded in 10% of our patients, a rate similar to that observed with bortezomib alone. 25 However, the majority of these patients (5 of 6) had already grade 1 PN due to prior therapy with thalidomide at study initiation.
At baseline, despite the continuous use of zoledronic acid, our patients had increased bone resorption and diminished bone formation markers. CTX is a well-established marker of bone resorption that reflects the extent of bone disease in MM. 26 CTX is also a useful marker of disease progression, development of osteolysis and response to treatment in MM, although it appears to be a better marker, when using consecutive measurements to follow development in MM, than the more widely studied markers NTX and ICTP. 27 In our study CTX was elevated in patients with extended lytic disease at baseline and its levels correlated with osteoclast activity as assessed by TRACP-5b levels. This increased osteoclast function seems to be due to the overproduction of several osteoclast regulators (RANKL, MIP-1a and OPN) that were found increased in the serum of our patients. Similar observations have been reported in newly diagnosed patients. 17, 18, [28] [29] [30] The independent prognostic value of sRANKL/OPG ratio for OS, and TTP in our study, which had been also reported previously for newly diagnosed patients, 28 and of Ang for TTP and of Dkk-1 for TtNT and OS, highlights the importance of interactions between myeloma cells and their microenvironment. Bone lytic disease by conventional skeletal surveys does not seem to correlate with survival, 31 although in our study markers of osteoclast/osteoblast regulation were independent predictors for survival. This finding may indicate that these markers may reflect more accurately the tumor burden than lytic disease assessed by plain X-rays does. This hypothesis is further strengthened by the independent prognostic value of other bone metabolism markers (that is, NTX and ICTP) for OS, disease progression and skeletal-related events in myeloma. 32, 33 These findings also support the measurement of bone metabolism markers in myeloma patients; however, larger studies will define which the best marker is, whether we need combination of markers and at what time points the measurements of these markers have to be performed.
VMDT regimen effectively reduced serum levels of all osteoclast stimulators (even more efficiently than V±D and TD for MIP-1a/OPN) and subsequent bone resorption. VMDT reduced sRANKL/OPG and bone resorption markers at a similar fashion with TD (although earlier for sRANKL/OPG) or V ± D and this is mainly considered as a tumor-reducing effect. Bortezomib has a strong anabolic effect on bones. 12, [34] [35] [36] [37] In this study, its combination with MDT, despite reduced Dkk-1 levels, produced only a marginal increase in bALP and a higher in OC and CICP. However, this increase in bALP and OC was not statistically significant and definitely lower than that observed with V ± D may be due to the administration of dexamethasone in all patients and of thalidomide; both dexamethasone and thalidomide are known to reduce bone V±D (n =34) TD (n =35) Figure 2 Bortezomib with or without dexamethasone increases serum levels of bone-specific alkaline phosphatase (bALP), whereas its combination with MDT or TD alone has no effect on serum bALP.
VMDT regimen in refractory/relapsed myeloma E Terpos et al formation markers. 38, 39 Furthermore, the dosage of bortezomib used in the VMDT regimen was lower than that used in the V ± D scheme. In spite of this, it is very important that during study period only one patient developed a pathological fracture due to disease progression and this may be due to the protecting effect of bortezomib in combination with zoledronic acid on bones. This, however, has to be proven in larger trials with clinical end points, such as bone mineral density measurements and evaluation of skeletal-related events.
VMDT reduced the levels of VEGF, Ang, Ang-2 and bFGF, irrespective of response, showing either a direct or indirect effect on angiogenesis, whereas TD and V ± D increased VEGF and bFGF. This result may suggest a stronger effect on angiogenic cytokines of VMDT compared with TD or V ± D. The independent prognostic value of Ang for TTP in our study strongly supports the role of angiogenesis in myeloma cell survival. In addition, we found strong correlations between the percent reductions of sRANKL/OPG, OPN and VEGF. Recent reports have shown that osteoclast-derived OPN and VEGF from myeloma cells cooperatively enhance angiogenesis and also induce osteoclastogenic activity by vascular endothelial cells. 40 These observations suggest the presence of a close link between myeloma cells, osteoclasts and vascular endothelial cells to form a vicious cycle between bone destruction, angiogenesis and myeloma expansion, and further support the significance of VMDT regimen in inhibiting these interactions.
The changes of markers of bone remodeling and angiogenesis (with the exception of sRANKL, MIP-1a and Ang-2) occurred regardless of response to therapy. Similar observations have been also reported previously with V ± D, 41 and may reflect an indirect effect of VMDT on osteoblast/osteoclast interactions and angiogenesis, which is irrespective of its direct effect on myeloma burden. This indirect effect seems to occur mainly during the first four cycles as no further improvement was observed in bone and angiogenesis markers beyond cycle 4 ( Table 5) .
We conclude that the VMDT regimen with intermittent thalidomide is able to induce rapid response in most patients with relapsed/refractory myeloma, with manageable toxicity. VMDT also improves abnormal bone remodeling and alters serum levels of angiogenic cytokines, highlighting its effect both on myeloma cells and on marrow microenvironment. VMDT regimen in refractory/relapsed myeloma E Terpos et al
